NCT05414500招募中1 期
Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Rates of Adverse Events
研究概览
简要总结
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab.
The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to understand and comply with study procedure, understand the risks involved in the study and provide written informed consent before the first study-specific procedure
- •Men or women >18 years with pathologically confirmed diagnosis of Sezary Syndrome or Mycosis fungoides
- •Must have CD30 positivity on recent biopsy of >1%
- •Stage II-IV, for skin only disease >20% BSA should be involved, large cell transformation is allowed.
- •Must have received at least one prior systemic therapy like bexarotene, interferons, ECP, methotrexate, Gemcitabine, Vorinostat etc. (patients who have received only skin directed therapy are not allowed)
- •ECOG performance status of 0,1 or 2
- •Adequate organ function at screening defined as follows
- •Hepatic: T bili <2 X ULN, isolated bilirubin of >2 is accepted if there is suspected diagnosis of Gilbert's syndrome, AST and ALT <3X ULN
- •Renal: estimated GFR >40 mL/Min/1.73 m2
- •Cardiac: LVEF >40%
- •Patients must have completed any chemotherapy, radiation therapy, or biologic therapy specific to their neoplasm ≥ 1 weeks or 5 half-lives (whichever is longer). Radiation for palliation on symptomatic lesions has no wash out period.
- •Expected life ≥ 4 months
- •Participants with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed if all of the following are met:
- •180 days or more have elapsed from the time of transplant
- •subject has been off systemic immunosuppressive medications (including but not limited to: cyclosporine, tacrolimus, mycophenolate mofetil, or corticosteroids) for at least 30 days prior to C1D
- •Topical steroids are permitted.
- •no signs or symptoms of acute graft versus host disease, other than Grade 1 skin involvement.
- •there are no signs or symptoms of chronic graft versus host disease
- •requiring systemic therapy
- •Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG], CTFG 2014) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. A woman is considered of childbearing potential (ie, fertile) following menarche and until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.
- •Subjects and their partners with reproductive potential must agree to use 2 highly effective contraceptive measures during the study and must agree not to become pregnant or father a child for 3 months after the last dose of study treatment. Contraceptive measures that may be considered highly effective comprise combined hormonal contraception (oral, vaginal, or transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence, and surgically successful vasectomy. Abstinence is acceptable only if it is consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of birth control.
排除标准
- •Prior exposure of BV < 6 months ago, or Moga. Prior exposure of BV is allowed if it is >6 months ago and CD30+ in >1% of in biopsy after last BV
- •Active CNS involvement by MF/Sezary Syndrome
- •Should not be receiving any other investigational agents. Prior use of investigational agents or other systemic therapy is allowed if it is >1 week ago or 5x half-life of the investigational agent whichever is shorter.
- •Pregnant and lactating women
- •Patients with clinically significant illness which would compromise participation in the study.
- •Severe or uncontrolled systemic infection. (active skin infections in CTCL/MF patients are allowed once course of antibiotics is completed and infection is under control)
- •Known HIV infection
- •Active Hepatitis B or C infection with active virus detected in blood. Hepatitis B core positive and HBsAg positivity are allowed if HBV DNA in blood is negative. Patient should be on antiviral prophylaxis. Hepatitis C positivity is allowed but HCV DNA by PCR must be negative in peripheral blood.
- •Uncontrolled DM, HTN, NYHA Grade III-IV CHF, unstable angina, Myocardial infarction within past 3 months, uncontrolled cardiac arrhythmia, uncontrolled psychiatric illness/social situation that would limit compliance with study requirements in the opinion of the investigator.
- •Grade 2 or more peripheral sensory or motor neuropathy
- •Prior severe allergic or anaphylactic reaction to monoclonal antibody or BV.
- •History of solid organ transplant
- •History of a second malignancy, excluding non-melanoma skin cell cancer within past 2 years.
研究组 & 干预措施
Cohort
Experimental
Fixed dose of Mogamulizumab and dose de-escalation with Brentuximab Vedotin
干预措施: Mogamulizumab (Drug)
Cohort
Experimental
Fixed dose of Mogamulizumab and dose de-escalation with Brentuximab Vedotin
干预措施: Brentuximab vedotin (Drug)
结局指标
主要结局
Rates of Adverse Events
时间窗: through study completion, an average of 1 year
To determine safety, tolerability, and recommended dose of combination of Brentuximab Vedotin and Mogamulizmab in patients with Cutaneous T-Cell Lymphoma and Mycosis Fungoides.
Rates of Serious Adverse Events
时间窗: At the end of cycle 1 (each cycle is 28 days)
To determine safety, tolerability, and recommended dose of combination of Brentuximab Vedotin and Mogamulizmab in patients with Cutaneous T-Cell Lymphoma and Mycosis Fungoides.
次要结局
- Duration of Response(through study completion, an average of 1 year)
- Overall Response rate(through study completion, an average of 1 year)
研究者
Amitkumar Mehta, MD
Associate Professor
University of Alabama at Birmingham
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung CancerNon-Small Cell Lung CancerNCT02358473Kyowa Kirin, Inc.13
已完成
1 期
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid TumorsSolid TumorsNCT02350673Hoffmann-La Roche70
已完成
1 期
Single Center Study Using Omalizumab in Subjects With Atopic DermatitisAtopic DermatitisNCT01678092Stanford University8
招募中
2 期
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasCutaneous T Cell LymphomaFungoides Mycosis Sezary SyndromeNCT05956041University of Michigan Rogel Cancer Center23
已完成
1 期
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT00103558Biogen31